Fortress Biotech, Inc. (FBIOP) Cost of Revenue (2016 - 2026)

Fortress Biotech's Cost of Revenue history runs 10 years deep, the most recent figure standing at $5.4 million for Q4 2025.

• In Q4 2025, Cost of Revenue rose 16.24% year-over-year to $5.4 million; the TTM figure through Dec 2025 stood at $20.9 million (changed 0.21% YoY), while the FY2025 annual figure was $20.9 million, changed 0.22% from the prior year.
• Cost of Revenue for Q4 2025 stood at $5.4 million, down from $5.8 million in the prior quarter.
• The five-year high for Cost of Revenue was $11.2 million in Q3 2021, with the low at $2.2 million in Q4 2023.
• The 5-year median for Cost of Revenue is $6.2 million (2023), against an average of $6.4 million.
• The sharpest annual moves came in 2021 and 2023: Cost of Revenue soared 230.48% in 2021, then tumbled 70.87% in 2023.
• Fortress Biotech's Cost of Revenue stood at $9.5 million in 2021, then fell by 18.97% to $7.7 million in 2022, then sank by 70.87% to $2.2 million in 2023, then soared by 108.19% to $4.7 million in 2024, then climbed by 16.24% to $5.4 million in 2025.
• Business Quant data shows FBIOP's Cost of Revenue at $5.4 million in Q4 2025, $5.8 million in Q3 2025, and $4.9 million in Q2 2025.